Modulation of Microglial by Nicotinic Medications
AssigneeUniversity of South Florida
InventorsDoug Shytle, Jun Tan, Francisco Fernandez
Life of this patent
Estimating the term…
Abstract
A method of treating a subject suffering from a neurodegenerative disease by modulating microglial activation with a therapeutically effective amount of a cholinergic agonist and a cholinesterase inhibitor. In one embodiment of the invention, the cholinergic agonist is nicotine and the cholinesterase is galantamine (a relatively weak acetylcholinesterase inhibitor and a potent allosteric potentiating ligand of nAChRs)
Claims19
A method of treating a subject afflicted with a neurodegenerative disorder, comprising the step of concomitantly administering a therapeutically effective amount of a cholinergic agonist and a cholinesterase inhibitor to the subject.
A method of treating a subject afflicted with a neurodegenerative disorder, comprising the step of concomitantly administering to the subject a therapeutically effective amount of nicotine and galantamine, wherein the target cell is a microglia.
A method of modulating microglial activation in a subject, comprising the step of concomitantly administering to the subject a therapeutically effective amount of a cholinergic agonist and a cholinesterase inhibitor.
A method of modulating microglial activation in a subject, comprising the step of concomitantly administering to the subject a therapeutically effective amount of nicotine and galantamine.
Dependencies are inferred from the claim text.